Creative Biolabs expands antibody discovery services for S. aureus AAC development

Creative Biolabs has added preclinical antibody discovery support for antibody-antibiotic conjugate programs targeting Staphylococcus aureus and MRSA. The updated service is meant to help pharma teams and academic labs move faster from antigen selection to early feasibility data.

Why it matters: - Antibody-antibiotic conjugates are drawing interest as a targeted way to fight antibiotic-resistant infections. - Creative Biolabs is positioning its preclinical services to help researchers build AAC candidates against S. aureus and methicillin-resistant S. aureus, or MRSA. - The new offering could reduce early-stage friction around antigen selection, screening and feasibility testing.

What happened: - Creative Biolabs expanded its preclinical antibody discovery support with tailored workflows for AAC development. - The service is designed for global pharmaceutical scientists and academic laboratories working on S. aureus and MRSA. - The company introduced the updated suite from Shirley, New York. - Creative Biolabs said the service is available through its company announcement.

The details: - The discovery workflow runs from antigen design and immunization through high-throughput antibody screening. - Creative Biolabs says the service acts as a technical extension of a client’s lab. - The company focuses on documented S. aureus biomarkers to help researchers choose surface antigens that remain expressed during infection. - IsdB, or iron-regulated surface determinant B, is a target in the service lineup. - IsdB is a transport protein tied to bacterial iron scavenging under host iron restriction. - The company also offers PBP2a-specific antibody discovery for MRSA-focused programs. - PBP2a, or penicillin-binding protein 2a, is the primary structural determinant of β-lactam resistance. - Creative Biolabs also provides technical infrastructure for assay development, affinity maturation and conjugate analytical support. - The updated S. aureus service matrix is designed to produce reproducible in vitro data before clients move to in vivo efficacy testing.

Between the lines: - Early AAC development has to balance target selection, linker chemistry and conjugate stability. - Focusing on IsdB and PBP2a suggests Creative Biolabs is aiming at well-characterized bacterial vulnerabilities rather than broad, untargeted screening. - The contract research model lets Creative Biolabs support discovery without taking on downstream clinical development risk.

What's next: - Creative Biolabs expects the service to help clients generate feasibility data earlier in the AAC pipeline. - Researchers can use the updated offering to refine lead antibodies before moving into animal studies. - The company is likely to see demand from teams looking for specialized preclinical support against gram-positive pathogens.